- cafead Nov 13, 2024 at 11:42: AM
via Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping 85% off the share price of the beleaguered biotech.
The phase 3 trial was assessing the effect of using the retinoic acid receptor alpha agonist tamibarotene in combination with azacitidine in newly diagnosed, higher-risk myelodysplastic syndrome (MDS) patients.
article source
The phase 3 trial was assessing the effect of using the retinoic acid receptor alpha agonist tamibarotene in combination with azacitidine in newly diagnosed, higher-risk myelodysplastic syndrome (MDS) patients.
article source